Trial · NCT04576988
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and had a baseline value of 6MWD. | meters | MEDIAN |
| PRIMARY | Number of Participants Who Experienced an Adverse Event (AE) | Up to approximately 24 weeks | All randomized participants who received at least one dose of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Discontinued Study Treatment Due to an AE | Up to approximately 24 weeks | All randomized participants who received at least one dose of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in the Percentage of Participants Achieving Multicomponent Improvement at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline measurement for the multicomponent improvement. | Percent change | NUMBER |
| SECONDARY | Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline measurement for the PVR. | dynes*sec/cm^5 | MEDIAN |
| SECONDARY | Change From Baseline in NT-proBNP Levels at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline measurement for the NT-proBNP levels. | pg/mL | MEDIAN |
| SECONDARY | Change From Baseline in the Percentage of Participants Who Improve in WHO FC at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline measurement for the WHO FC. | Percent change | NUMBER |
| SECONDARY | Time to Death or the First Occurrence of Clinical Worsening Event | Up to approximately 18 months | All randomized participants who received at least one dose of study treatment and who died or experienced a first clinical worsening event. | Weeks | MEDIAN |
| SECONDARY | Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline measurement for the low risk score. | Percent Change | NUMBER |
| SECONDARY | Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT®) at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline physical impact domain score. | Score on a scale | MEDIAN |
| SECONDARY | Change From Baseline in the Cardiopulmonary Symptoms Domain Score of PAH-SYMPACT® at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline cardiopulmonary domain score. | Score on a scale | MEDIAN |
| SECONDARY | Change From Baseline in the Cognitive/Emotional Impacts Domain Score of PAH-SYMPACT® at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had a baseline cognitive/emotional impacts domain score. | Score on a scale | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04576988/outcomes